Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.770 +0.240 (+15.69%)

Streaming Delayed Price Updated: 11:44 AM EDT, May 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	4,372,952
Open	1.540
Bid (Size)	1.770 (2,100)
Ask (Size)	1.780 (4,600)
Prev. Close	1.530
Today's Range	1.530 - 1.855
52wk Range	0.9100 - 1.940
Shares Outstanding	98,384,456
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Today 9:00 EDT

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

May 01, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+79.4%	+79.4%
1 Month	+45.1%	+45.1%
3 Month	+43.9%	+43.9%
6 Month	+40.5%	+40.5%
1 Year	+35.1%	+35.1%

More News

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

April 30, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR

April 16, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

April 09, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

March 18, 2026

From USA News Group

Via GlobeNewswire

Friday's after hours session: top gainers and losers ↗

March 13, 2026

Via Chartmill

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

March 04, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

March 03, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

February 26, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

February 03, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

January 23, 2026

From Equity Insider

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

January 05, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

December 08, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

November 13, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

November 04, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

October 26, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures

October 20, 2025

Via MarketMinute

Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

October 14, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 30, 2025

Via Benzinga

Fate Therapeutics to Present at Upcoming Investor Conferences

August 25, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

September 03, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Fate Therapeutics, Inc. - Common Stock publicly traded?

Yes, Fate Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Fate Therapeutics, Inc. - Common Stock trade on?

Fate Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Fate Therapeutics, Inc. - Common Stock?

The ticker symbol for Fate Therapeutics, Inc. - Common Stock is FATE on the Nasdaq Stock Market

What is the current price of Fate Therapeutics, Inc. - Common Stock?

The current price of Fate Therapeutics, Inc. - Common Stock is 1.770

When was Fate Therapeutics, Inc. - Common Stock last traded?

The last trade of Fate Therapeutics, Inc. - Common Stock was at 05/04/26 11:44 AM ET

What is the market capitalization of Fate Therapeutics, Inc. - Common Stock?

The market capitalization of Fate Therapeutics, Inc. - Common Stock is 174.14M

How many shares of Fate Therapeutics, Inc. - Common Stock are outstanding?

Fate Therapeutics, Inc. - Common Stock has 174M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.